{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:43:38Z","timestamp":1790847818521,"version":"4.1.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.autrev.2011.08.005","type":"journal-article","created":{"date-parts":[[2011,8,21]],"date-time":"2011-08-21T04:02:40Z","timestamp":1313899360000},"page":"88-97","source":"Crossref","is-referenced-by-count":77,"title":["Autoimmune disease: A role for new anti-viral therapies?"],"prefix":"10.1016","volume":"11","author":[{"given":"David H.","family":"Dreyfus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2011.08.005_bb0005","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaci.2008.07.006","article-title":"Treatment of chronic autoimmune urticaria with omalizumab","volume":"122","author":"Kaplan","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.autrev.2011.08.005_bb0015","first-page":"171","article-title":"The syndrome of thyroid autoimmunity and idiopathic chronic urticaria and angioedema presenting as anaphylaxis","volume":"24","author":"Dreyfus","year":"2003","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.autrev.2011.08.005_bb0020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S1081-1206(10)60069-5","article-title":"Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema","volume":"100","author":"Dreyfus","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2222.2009.03256.x","article-title":"Pathogenesis of chronic urticaria","volume":"39","author":"Kaplan","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.autrev.2011.08.005_bb0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/cmi.2010.70","article-title":"Explosion of autoimmune diseases and the mosaic of old and novel factors","volume":"8","author":"Agmon-Levin","year":"2011","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0035","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1196\/annals.1422.059","article-title":"Epstein\u2013Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report","volume":"1108","author":"Barzilai","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2011.08.005_bb0040","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.anai.2010.06.011","article-title":"Development of a daily diary for patients with chronic idiopathic urticaria","volume":"105","author":"Mathias","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H(1)-antihistamine-refractory chronic idiopathic urticaria","author":"Saini","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0050","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcv.2007.02.002","article-title":"A virologic pilot study of valacyclovir in infectious mononucleosis","volume":"39","author":"Balfour","year":"2007","journal-title":"J Clin Virol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0055","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1191\/1352458505ms1185oa","article-title":"A randomized clinical trial of valacyclovir in multiple sclerosis","volume":"11","author":"Friedman","year":"2005","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2011.08.005_bb0060","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1128\/JVI.02487-09","article-title":"The Epstein\u2013Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production","volume":"84","author":"Meng","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.autrev.2006.08.014","article-title":"What is after cytokine-blocking therapy, a novel therapeutic target-synovial Epstein\u2013Barr virus for rheumatoid arthritis","volume":"6","author":"Sawada","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.08.005_bb0070","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1081-1206(10)61083-6","article-title":"The DDE recombinases: diverse roles in acquired and innate immunity","volume":"97","author":"Dreyfus","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0075","doi-asserted-by":"crossref","first-page":"e5778","DOI":"10.1371\/journal.pone.0005778","article-title":"Paleo-immunology: evidence consistent with insertion of a primordial herpes virus-like element in the origins of acquired immunity","volume":"4","author":"Dreyfus","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2011.08.005_bb0080","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1073\/pnas.1007144107","article-title":"Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain","volume":"107","author":"Nadal","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.autrev.2011.08.005_bb0085","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection","volume":"359","author":"Cooper","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.08.005_bb0090","doi-asserted-by":"crossref","first-page":"20057","DOI":"10.1073\/pnas.1010246107","article-title":"Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance","volume":"107","author":"Hare","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.autrev.2011.08.005_bb0095","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.4155\/fmc.10.199","article-title":"Authentic HIV-1 integrase inhibitors","volume":"2","author":"Liao","year":"2010","journal-title":"Future Med Chem"},{"key":"10.1016\/j.autrev.2011.08.005_bb0100","doi-asserted-by":"crossref","first-page":"20865","DOI":"10.1073\/pnas.0908074106","article-title":"Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir","volume":"106","author":"Beck-Engeser","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.autrev.2011.08.005_bb0105","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1742-4690-6-104","article-title":"B cells and monocytes from patients with active multiple sclerosis exhibit increased surface expression of both HERV-H Env and HERV-W Env, accompanied by increased seroreactivity","volume":"6","author":"Brudek","year":"2009","journal-title":"Retrovirology"},{"key":"10.1016\/j.autrev.2011.08.005_bb0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.virol.2008.11.025","article-title":"EBV LMP-2A employs a novel mechanism to transactivate the HERV-K18 superantigen through its ITAM","volume":"385","author":"Hsiao","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.autrev.2011.08.005_bb0115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2009.08.015","article-title":"Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytokine production, and the lectin complement activation pathway in multiple sclerosis","volume":"215","author":"Petersen","year":"2009","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0120","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1128\/JVI.78.14.7852-7860.2004","article-title":"Epstein\u2013Barr virus latent membrane protein LMP-2A is sufficient for transactivation of the human endogenous retrovirus HERV-K18 superantigen","volume":"78","author":"Sutkowski","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1074-7613(01)00210-2","article-title":"Epstein\u2013Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen","volume":"15","author":"Sutkowski","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2011.08.005_bb0130","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.184.3.971","article-title":"An Epstein\u2013Barr virus-associated superantigen","volume":"184","author":"Sutkowski","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2011.08.005_bb0135","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.4049\/jimmunol.177.5.3178","article-title":"Murine Vbeta3+ and Vbeta7+ T cell subsets are specific targets for the HERV-K18 Env superantigen","volume":"177","author":"Tai","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0140","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1098\/rstb.2000.0774","article-title":"Historical background","volume":"356","author":"Epstein","year":"2001","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.autrev.2011.08.005_bb0145","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cellimm.2005.04.006","article-title":"Six questions about the hygiene hypothesis","volume":"233","author":"Bach","year":"2005","journal-title":"Cell Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04139.x","article-title":"The \u2018hygiene hypothesis\u2019 for autoimmune and allergic diseases: an update","volume":"160","author":"Okada","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0155","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaci.2005.05.038","article-title":"EBV the prototypical human tumor virus\u2014just how bad is it?","volume":"116","author":"Thorley-Lawson","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0160","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.it.2008.01.006","article-title":"Epstein\u2013Barr virus: a paradigm for persistent infection\u2014for real and in virtual reality","volume":"29","author":"Thorley-Lawson","year":"2008","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0165","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2007-06-093278","article-title":"On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis","volume":"111","author":"Hadinoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2011.08.005_bb0170","doi-asserted-by":"crossref","first-page":"e1000496","DOI":"10.1371\/journal.ppat.1000496","article-title":"The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output","volume":"5","author":"Hadinoto","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.autrev.2011.08.005_bb0175","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1128\/JVI.02609-08","article-title":"The intersection of Epstein\u2013Barr virus with the germinal center","volume":"83","author":"Roughan","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0180","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-065X.1996.tb00912.x","article-title":"Epstein\u2013Barr virus infection of T cells: implications for altered T-lymphocyte activation, repertoire development and autoimmunity","volume":"152","author":"Dreyfus","year":"1996","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2011.08.005_bb0185","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.4049\/jimmunol.175.6.3460","article-title":"Role of T cells in EBV-infected systemic lupus erythematosus patients","volume":"175","author":"Dreyfus","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0190","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cair.2005.01.005","article-title":"Immunopathology associated with Epstein\u2013Barr Virus (EBV) infection: evidence for interactions with T-lymphocyte EBV receptor CD21","volume":"5","author":"Dreyfus","year":"2005","journal-title":"Clin Appl Immunol Rev"},{"key":"10.1016\/j.autrev.2011.08.005_bb0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/jinf.2001.0898","article-title":"Reflections on Epstein\u2013Barr virus: some recently resolved old uncertainties","volume":"43","author":"Epstein","year":"2001","journal-title":"J Infect"},{"key":"10.1016\/j.autrev.2011.08.005_bb0200","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nrmicro2015","article-title":"The curious case of the tumour virus: 50years of Burkitt's lymphoma","volume":"6","author":"Thorley-Lawson","year":"2008","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0205","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12026-008-8048-7","article-title":"X-linked lymphoproliferative disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses","volume":"42","author":"Bassiri","year":"2008","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2011.08.005_bb0210","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nm1189","article-title":"Regulation of NKT cell development by SAP, the protein defective in XLP","volume":"11","author":"Nichols","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2011.08.005_bb0215","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2010-07-298372","article-title":"Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1\/SAP deficiency) versus type 2 (XLP-2\/XIAP deficiency)","volume":"117","author":"Pachlopnik Schmid","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2011.08.005_bb0220","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJM198111193052102","article-title":"Defective EBV-specific suppressor T-cell function in rheumatoid arthritis","volume":"305","author":"Tosato","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.08.005_bb0225","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1172\/JCI111388","article-title":"Abnormally elevated frequency of Epstein\u2013Barr virus-infected B cells in the blood of patients with rheumatoid arthritis","volume":"73","author":"Tosato","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2011.08.005_bb0230","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/intimm\/9.5.739","article-title":"Detection of Epstein\u2013Barr virus-encoded small RNA 1 and latent membrane protein 1 in synovial lining cells from rheumatoid arthritis patients","volume":"9","author":"Takei","year":"1997","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0235","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00286137","article-title":"Epstein\u2013Barr virus-specific cytotoxic T cell responses in rheumatoid arthritis patients","volume":"2","author":"Gaston","year":"1982","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2011.08.005_bb0240","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/art.10933","article-title":"Epstein\u2013Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction","volume":"48","author":"Balandraud","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.08.005_bb0245","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.autrev.2004.02.002","article-title":"Epstein\u2013Barr virus and rheumatoid arthritis","volume":"3","author":"Balandraud","year":"2004","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.08.005_bb0250","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.autrev.2004.08.034","article-title":"Epstein\u2013Barr virus etiology in rheumatoid synovitis","volume":"4","author":"Sawada","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.08.005_bb0255","article-title":"The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials","author":"Lee","year":"2010","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2011.08.005_bb0260","first-page":"45","article-title":"Epstein\u2013Barr virus infection induces lupus autoimmunity","volume":"64","author":"Harley","year":"2006","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1016\/j.autrev.2011.08.005_bb0265","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/01.bor.0000240355.37927.94","article-title":"Epstein\u2013Barr virus and systemic lupus erythematosus","volume":"18","author":"James","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0270","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1172\/JCI119856","article-title":"An increased prevalence of Epstein\u2013Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus","volume":"100","author":"James","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2011.08.005_bb0275","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/1529-0131(200105)44:5<1122::AID-ANR193>3.0.CO;2-D","article-title":"Systemic lupus erythematosus in adults is associated with previous Epstein\u2013Barr virus exposure","volume":"44","author":"James","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.08.005_bb0280","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.4049\/jimmunol.172.2.1287","article-title":"Defective control of latent Epstein\u2013Barr virus infection in systemic lupus erythematosus","volume":"172","author":"Kang","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0285","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/08916930500484849","article-title":"Epstein\u2013Barr virus and molecular mimicry in systemic lupus erythematosus","volume":"39","author":"Poole","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2011.08.005_bb0290","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.autrev.2008.12.008","article-title":"Aberrant Epstein\u2013Barr viral infection in systemic lupus erythematosus","volume":"8","author":"Poole","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.08.005_bb0295","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.27408","article-title":"Epstein\u2013Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells","volume":"62","author":"Quan","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.08.005_bb0300","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/art.21682","article-title":"An altered immune response to Epstein\u2013Barr nuclear antigen 1 in pediatric systemic lupus erythematosus","volume":"54","author":"McClain","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.08.005_bb0305","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.4049\/jimmunol.174.11.6599","article-title":"EBV and systemic lupus erythematosus: a new perspective","volume":"174","author":"Gross","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0310","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-010-1387-5","article-title":"Off-label use of rituximab in systemic lupus erythematosus: a systematic review","volume":"29","author":"Murray","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0315","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00001648-200003000-00023","article-title":"Epstein\u2013Barr virus and multiple sclerosis","volume":"11","author":"Ascherio","year":"2000","journal-title":"Epidemiology"},{"key":"10.1016\/j.autrev.2011.08.005_bb0320","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1001\/jama.286.24.3083","article-title":"Epstein\u2013Barr virus antibodies and risk of multiple sclerosis: a prospective study","volume":"286","author":"Ascherio","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2011.08.005_bb0325","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/intimm\/dxq463","article-title":"Impaired IFN-gamma production and proliferation of NK cells in multiple sclerosis","volume":"23","author":"Lunemann","year":"2011","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0330","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/brain\/awl067","article-title":"Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis","volume":"129","author":"Lunemann","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2011.08.005_bb0335","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1212\/01.wnl.0000326576.91097.87","article-title":"Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis","volume":"71","author":"Lunemann","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2011.08.005_bb0340","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1084\/jem.20072397","article-title":"EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2","volume":"205","author":"Lunemann","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2011.08.005_bb0345","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.it.2009.03.007","article-title":"EBV in MS: guilty by association?","volume":"30","author":"Lunemann","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0350","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ana.21886","article-title":"Elevated Epstein\u2013Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis","volume":"67","author":"Lunemann","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0355","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.autrev.2009.01.017","article-title":"Preventing and curing multiple sclerosis by controlling Epstein\u2013Barr virus infection","volume":"8","author":"Pender","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.08.005_bb0360","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1073858410381531","article-title":"The essential role of epstein\u2013barr virus in the pathogenesis of multiple sclerosis","volume":"17","author":"Pender","year":"2011","journal-title":"Neuroscientist"},{"key":"10.1016\/j.autrev.2011.08.005_bb0365","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/jnnp.2008.161018","article-title":"Decreased T cell reactivity to Epstein\u2013Barr virus infected lymphoblastoid cell lines in multiple sclerosis","volume":"80","author":"Pender","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2011.08.005_bb0370","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-2377-11-95","article-title":"Decreased CD8+ T cell response to Epstein\u2013Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes","volume":"11","author":"Pender","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0375","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2011-300213","article-title":"CD8 T cell deficiency impairs control of Epstein\u2013Barr virus and worsens with age in multiple sclerosis","author":"Pender","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2011.08.005_bb0380","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbadis.2010.06.012","article-title":"Viral triggers of multiple sclerosis","volume":"1812","author":"Kakalacheva","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.autrev.2011.08.005_bb0385","doi-asserted-by":"crossref","DOI":"10.1177\/1352458511408991","article-title":"Anti-Epstein\u2013Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel","author":"Munger","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2011.08.005_bb0390","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1093\/brain\/awq223","article-title":"Detection of Epstein\u2013Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look","volume":"133","author":"Aloisi","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2011.08.005_bb0395","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/NEN.0b013e3181e332ec","article-title":"Epstein\u2013Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation","volume":"69","author":"Serafini","year":"2010","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0400","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11910-008-0064-4","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"8","author":"Bourdette","year":"2008","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.autrev.2011.08.005_bb0405","first-page":"2646","article-title":"Rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Chaudhuri","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.08.005_bb0410","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","article-title":"B cells as therapeutic targets in autoimmune neurological disorders","volume":"4","author":"Dalakas","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0415","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.08.005_bb0420","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1007\/s00415-008-0956-x","article-title":"Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity","volume":"255","author":"Leussink","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0425","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1600-0404.2007.00958.x","article-title":"Rituximab in a patient with multiple sclerosis\u2014effect on B cells, plasma cells and intrathecal IgG synthesis","volume":"117","author":"Petereit","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2011.08.005_bb0430","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1586\/1744666X.4.5.573","article-title":"Use of rituximab in multiple sclerosis: current progress and future perspectives","volume":"4","author":"Reske","year":"2008","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0435","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMc080557","article-title":"Rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Schrijver","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.08.005_bb0440","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.autrev.2010.09.010","article-title":"Do infections facilitate the emergence of systemic sclerosis?","volume":"10","author":"Grossman","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.08.005_bb0445","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaut.2010.06.001","article-title":"TLR-mediated up-regulation of serum retroviral gp70 is controlled by the Sgp loci of lupus-prone mice","volume":"35","author":"Baudino","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2011.08.005_bb0450","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.autrev.2010.07.012","article-title":"Role of endogenous retroviruses in murine SLE","volume":"10","author":"Baudino","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.08.005_bb0455","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/0091270009351884","article-title":"Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein\u2013Barr virus infectious mononucleosis","volume":"50","author":"Vezina","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0460","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1126\/science.7801124","article-title":"Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases","volume":"266","author":"Dyda","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.autrev.2011.08.005_bb0465","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1073\/pnas.95.16.9150","article-title":"Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium","volume":"95","author":"Goldgur","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.autrev.2011.08.005_bb0470","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jviromet.2010.06.004","article-title":"Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay","volume":"168","author":"Michelini","year":"2010","journal-title":"J Virol Methods"},{"key":"10.1016\/j.autrev.2011.08.005_bb0475","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.08.005_bb0480","doi-asserted-by":"crossref","first-page":"e6877","DOI":"10.1371\/journal.pone.0006877","article-title":"Raltegravir cerebrospinal fluid concentrations in HIV-1 infection","volume":"4","author":"Yilmaz","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2011.08.005_bb0485","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/318287a0","article-title":"Protection of cottontop tamarins against Epstein\u2013Barr virus-induced malignant lymphoma by a prototype subunit vaccine","volume":"318","author":"Epstein","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2011.08.005_bb0490","first-page":"485","article-title":"Not all potently neutralizing, vaccine-induced antibodies to Epstein\u2013Barr virus ensure protection of susceptible experimental animals","volume":"63","author":"Epstein","year":"1986","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0495","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jmv.1890290114","article-title":"Validation of a first-generation Epstein\u2013Barr virus vaccine preparation suitable for human use","volume":"29","author":"Morgan","year":"1989","journal-title":"J Med Virol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0500","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1073\/pnas.79.23.7504","article-title":"Purified Epstein\u2013Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes","volume":"79","author":"North","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.autrev.2011.08.005_bb0505","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/08916930902785363","article-title":"Intravenous immunoglobulin therapy for autoimmune diseases","volume":"42","author":"Arnson","year":"2009","journal-title":"Autoimmunity"},{"issue":"Suppl 2","key":"10.1016\/j.autrev.2011.08.005_bb0510","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.2011.04387.x","article-title":"Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy","volume":"164","author":"Kaveri","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2011.02.007","article-title":"Comparison of different IVIg preparations on IL-17 production by human Th17 cells","author":"Maddur","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2011.08.005_bb0520","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1358\/dnp.2000.13.2.858466","article-title":"Peptide immunotherapy in autoimmune diseases","volume":"13","author":"Krause","year":"2000","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.autrev.2011.08.005_bb0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevImmunol.v20.i1.10","article-title":"Immunomodulation of experimental autoimmune diseases via oral tolerance","volume":"20","author":"Krause","year":"2000","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0530","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jaut.2010.07.003","article-title":"\u2018ASIA\u2019\u2014autoimmune\/inflammatory syndrome induced by adjuvants","volume":"36","author":"Shoenfeld","year":"2011","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2011.08.005_bb0535","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide","volume":"75","author":"Stephenson","year":"1978","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.autrev.2011.08.005_bb0540","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1073\/pnas.83.12.4143","article-title":"Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA","volume":"83","author":"Zamecnik","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.autrev.2011.08.005_bb0545","first-page":"425","article-title":"Gene silencing in the therapy of influenza and other respiratory diseases: targeting to RNase P by use of External Guide Sequences (EGS)","volume":"1","author":"Dreyfus","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.autrev.2011.08.005_bb0550","doi-asserted-by":"crossref","first-page":"6328","DOI":"10.1073\/pnas.0914843107","article-title":"Functional delivery of viral miRNAs via exosomes","volume":"107","author":"Pegtel","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.autrev.2011.08.005_bb0555","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1126\/science.325_392c","article-title":"Immune system: success owed to a virus?","volume":"325","author":"Dreyfus","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.autrev.2011.08.005_bb0560","series-title":"Molecular Mechanisms of Ataxia Telangectasia","article-title":"Oncogenesis in ataxia telangectasia: roles of ATM, p53, Nf-kappa-B and DDE recombination pathogenesis","author":"Dreyfus","year":"2009"},{"key":"10.1016\/j.autrev.2011.08.005_bb0565","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMcibr074519","article-title":"Viral infections and nonspecific protection\u2014good or bad?","volume":"357","author":"Unanue","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.08.005_bb0570","first-page":"S12","article-title":"Bacterial triggers and autoimmune rheumatic diseases","volume":"26","author":"Girschick","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2011.08.005_bb0575","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/ard.60.5.433","article-title":"Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies","volume":"60","author":"Abu-Shakra","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.08.005_bb0580","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000314634","article-title":"Malignancies in autoimmune rheumatic diseases\u2014a mini-review","volume":"57","author":"Szekanecz","year":"2011","journal-title":"Gerontology"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211001753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211001753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T16:57:44Z","timestamp":1543597064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997211001753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":116,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1568997211001753"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2011.08.005","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}